Human Apolipoprotein AI ELISA Kit (ab189576)
Key features and details
- One-wash 90 minute protocol
- Sensitivity: 59 pg/ml
- Range: 0.313 ng/ml - 20 ng/ml
- Sample type: Cell culture supernatant, Cit plasma, EDTA Plasma, Hep Plasma, Serum
- Detection method: Colorimetric
- Assay type: Sandwich (quantitative)
- Reacts with: Human
Overview
-
Product name
Human Apolipoprotein AI ELISA Kit
See all Apolipoprotein A I kits -
Detection method
Colorimetric -
Precision
Intra-assay Sample n Mean SD CV% Overall 5 2.1% Inter-assay Sample n Mean SD CV% Overall 3 2.9% -
Sample type
Cell culture supernatant, Serum, Hep Plasma, EDTA Plasma, Cit plasma -
Assay type
Sandwich (quantitative) -
Sensitivity
59 pg/ml -
Range
0.313 ng/ml - 20 ng/ml -
Recovery
Sample specific recovery Sample type Average % Range Serum 115 111% - 122% Tissue Culture Media 89 85% - 92% Hep Plasma 95 76% - 111% EDTA Plasma 112 108% - 115% Cit plasma 119 117% - 123% -
Assay time
1h 30m -
Assay duration
One step assay -
Species reactivity
Reacts with: Human
Does not react with: Goat, Cow, Pig -
Product overview
Human Apolipoprotein AI ELISA Kit (ab189576) is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of Apolipoprotein AI protein in cell culture supernatant, cit plasma, edta plasma, hep plasma, and serum. It uses our proprietary SimpleStep ELISA® technology. Quantitate Human Apolipoprotein AI with 59 pg/ml sensitivity.
SimpleStep ELISA® technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA® plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA® protocol summary in the image section for further details. Our SimpleStep ELISA® technology provides several benefits:
- Single-wash protocol reduces assay time to 90 minutes or less
- High sensitivity, specificity and reproducibility from superior antibodies
- Fully validated in biological samples
- 96-wells plate breakable into 12 x 8 wells strips
A 384-well SimpleStep ELISA® microplate (ab203359) is available to use as an alternative to the 96-well microplate provided with SimpleStep ELISA® kits.
-
Notes
Apolipoprotein AI (ApoA1) is secreted by the liver and small intestine and is a major protein of plasma HDL (high density lipoprotein). APOA-I participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). Defects in APOA1I are associated with several diseases associated with low HDL levels (HDLD1 and HDLD2) and amyloidosis (AMYL8).
-
Platform
Microplate
Properties
-
Storage instructions
Store at +4°C. Please refer to protocols. -
Components 1 x 96 tests 10X Human APOA1 Capture Antibody 1 x 600µl 10X Human APOA1 Detector Antibody 1 x 600µl 10X Wash Buffer PT (ab206977) 1 x 20ml Antibody Diluent 5BI 1 x 6ml Human APOA1 Lyophilized Recombinant Protein 2 vials Plate Seals 1 unit Sample Diluent NS (ab193972) 1 x 50ml SimpleStep Pre-Coated 96-Well Microplate (ab206978) 1 unit Stop Solution 1 x 12ml TMB Development Solution 1 x 12ml -
Research areas
- Metabolism
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Lipid metabolism
- Metabolism
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Cholesterol Metabolism
-
Function
Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility. -
Tissue specificity
Major protein of plasma HDL, also found in chylomicrons. Synthesized in the liver and small intestine. -
Involvement in disease
Defects in APOA1 are a cause of high density lipoprotein deficiency type 2 (HDLD2) [MIM:604091]; also known as familial hypoalphalipoproteinemia (FHA). Inheritance is autosomal dominant.
Defects in APOA1 are a cause of the low HDL levels observed in high density lipoprotein deficiency type 1 (HDLD1) [MIM:205400]; also known as analphalipoproteinemia or Tangier disease (TGD). HDLD1 is a recessive disorder characterized by the absence of plasma HDL, accumulation of cholesteryl esters, premature coronary artery disease, hepatosplenomegaly, recurrent peripheral neuropathy and progressive muscle wasting and weakness. In HDLD1 patients, ApoA-I fails to associate with HDL probably because of the faulty conversion of pro-ApoA-I molecules into mature chains, either due to a defect in the converting enzyme activity or a specific structural defect in Tangier ApoA-I.
Defects in APOA1 are the cause of amyloid polyneuropathy-nephropathy Iowa type (AMYLIOWA) [MIM:107680]; also known as amyloidosis van Allen type or familial amyloid polyneuropathy type III. AMYLIOWA is a hereditary generalized amyloidosis due to deposition of amyloid mainly constituted by apolipoprotein A1. The clinical picture is dominated by neuropathy in the early stages of the disease and nephropathy late in the course. Death is due in most cases to renal amyloidosis. Severe peptic ulcer disease can occurr in some and hearing loss is frequent. Cataracts is present in several, but vitreous opacities are not observed.
Defects in APOA1 are a cause of amyloidosis type 8 (AMYL8) [MIM:105200]; also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash. -
Sequence similarities
Belongs to the apolipoprotein A1/A4/E family. -
Post-translational
modificationsPalmitoylated.
Phosphorylation sites are present in the extracelllular medium. -
Cellular localization
Secreted. - Information by UniProt
-
Alternative names
- Apo-AI
- ApoA I
- ApoA-I
see all -
Database links
- Entrez Gene: 335 Human
- Omim: 107680 Human
- SwissProt: P02647 Human
- Unigene: 93194 Human
Associated products
-
ELISA kits
-
Related Products
Images
-
Other - Human Apolipoprotein AI ELISA Kit (ab189576)
SimpleStep ELISA technology allows the formation of the antibody-antigen complex in one single step, reducing assay time to 90 minutes. Add samples or standards and antibody mix to wells all at once, incubate, wash, and add your final substrate. See protocol for a detailed step-by-step guide.
-
Example of Apolipoprotein A1 standard curve.Background-subtracted data values (mean +/- SD) are graphed.
-
Titration of Human serum and plasma (citrate)Human serum and plasma (citrate) diluted 2.5x105 –fold to 8x106 –fold in Sample Diluent NS. Background subtracted data from duplicate measurements are plotted.
-
Interpolated concentrations of Apolipoprotein A1 in Human serumInterpolated concentrations of Apolipoprotein A1 in Human serum and plasma heparin. The concentrations of Apolipoprotein A1 were measured in duplicate and interpolated from the Apolipoprotein A1 standard curve and corrected for sample dilution. The interpolated dilution factor corrected values are plotted (mean +/- SD, n=2). The mean Apolipoprotein A1 concentration was determined to be 2500 µg/mL in serum and 1053ug/mL in plasma heparin.
-
Interpolated concentrations of Apolipoprotein A1 in Human serum from 10 donors.Interpolated concentrations of Apolipoprotein A1 in Human serum from 10 donors. Serum from 10 apparently healthy male donors was measured in duplicate. The mean Apolipoprotein A1 concentration was determined to be 526 µg/mL with a range of 9.8-2011 µg/mL.
Datasheets and documents
-
SDS download
-
Datasheet download
References (5)
ab189576 has been referenced in 5 publications.
- Rogers MA et al. Retinoids Repress Human Cardiovascular Cell Calcification With Evidence for Distinct Selective Retinoid Modulator Effects. Arterioscler Thromb Vasc Biol 40:656-669 (2020). PubMed: 31852220
- Wang L et al. Identification of circular RNA Hsa_circ_0001879 and Hsa_circ_0004104 as novel biomarkers for coronary artery disease. Atherosclerosis 286:88-96 (2019). PubMed: 31103880
- Zhu C et al. Site-Specific Glycoprofiles of HDL-Associated ApoE are Correlated with HDL Functional Capacity and Unaffected by Short-Term Diet. J Proteome Res 18:3977-3984 (2019). PubMed: 31545048
- Gugliucci A et al. Short-term isocaloric fructose restriction lowers apoC-III levels and yields less atherogenic lipoprotein profiles in children with obesity and metabolic syndrome. Atherosclerosis N/A:N/A (2016). Sandwich ELISA ; Human . PubMed: 27451002
- Tavori H et al. Macrophage apoAI protects against dyslipidemia-induced dermatitis and atherosclerosis without affecting HDL. J Lipid Res N/A:N/A (2015). ELISA ; Human . PubMed: 25593328